Table 3 Treatment-related adverse events of all grades occurring in more than 15% of patients
Events, n (%) | All patients (n = 35) | ||
|---|---|---|---|
Any grade | Grade 1–2 | Grade 3 or higher | |
Aspartate aminotransferase increased | 34 (97.1) | 24 (68.6) | 10 (28.6) |
Alanine aminotransferase increased | 33 (94.3) | 26 (74.3) | 7 (20.0) |
Hypoalbuminemia | 31 (88.6) | 31 (88.6) | 0 |
Neutrophil count decreased | 29 (82.9) | 17 (48.6) | 12 (34.3) |
Lymphocyte count decreased | 27 (77.1) | 14 (40.0) | 13 (37.1) |
Anemia | 25 (71.4) | 23 (65.7) | 2 (5.7) |
Platelet count decreased | 23 (65.7) | 15 (42.9) | 8 (22.9) |
Blood bilirubin increased | 22 (62.9) | 19 (54.3) | 3 (8.6) |
Proteinuria | 22 (62.9) | 22 (62.9) | 0 |
Abdominal pain | 21 (60.0) | 21 (60.0) | 0 |
White blood cell decreased | 20 (57.1) | 14 (40.0) | 6 (17.1) |
Weight loss | 17 (48.6) | 17 (48.6) | 0 |
Anorexia | 17 (48.6) | 17 (48.6) | 0 |
Hyperglycemia | 16 (45.7) | 16 (45.7) | 0 |
Hyponatremia | 15 (42.9) | 14 (40.0) | 1 (2.9) |
Hyperuricemia | 15 (42.9) | 15 (42.9) | 0 |
Hypokalemia | 14 (40.0) | 12 (34.3) | 2 (5.7) |
Rash | 14 (40.0) | 12 (34.3) | 2 (5.7) |
Hypertension | 14 (40.0) | 9 (25.7) | 5 (14.3) |
Hand-foot syndrome | 13 (37.1) | 10 (28.6) | 3 (8.6) |
RCCEP | 13 (37.1) | 12 (34.3) | 1 (2.9) |
Diarrhea | 13 (37.1) | 12 (34.3) | 1 (2.9) |
Vomiting | 12 (34.3) | 12 (34.3) | 0 |
Fatigue | 11 (31.4) | 11 (31.4) | 0 |
Hematuria | 11 (31.4) | 11 (31.4) | 0 |
Upper respiratory infection | 9 (25.7) | 9 (25.7) | 0 |
Gingival hemorrhage | 9 (25.7) | 9 (25.7) | 0 |
Fever | 8 (22.9) | 8 (22.9) | 0 |
Oral mucositis | 8 (22.9) | 8 (22.9) | 0 |
Gingivitis | 8 (22.9) | 8 (22.9) | 0 |
Ascites | 7 (20.0) | 7 (20.0) | 0 |
Epistaxis | 7 (20.0) | 7 (20.0) | 0 |
Cough | 6 (17.1) | 6 (17.1) | 0 |
Headache | 6 (17.1) | 6 (17.1) | 0 |
